Engflag

Co-Eziday

Quick links to important sections

Co-Eziday

Co-Eziday_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Co-Eziday

Property Description
Active ingredient Losartan Potassium, Hydrochlorothiazide
Form Oral Tablet
Pharmacological class Angiotensin II Inhibitors with Thiazides
General purpose Blood Pressure Lowering
Origin Synthetic

What Type of Medicine is Co-Eziday?

Co-Eziday is a prescription-only Fixed-Dose Combination Product classified as an Antihypertensive Agent, designed for individuals requiring consistent management of high systemic blood pressure. This synthetic medicine is categorized within the pharmacological class of Angiotensin II Inhibitors with Thiazides, supplied as an Oral Tablet dosage form. The combined formulation, generically known as Losartan-Hydrochlorothiazide, provides a solid-form Combination Therapy that is clinically recognized for facilitating the simultaneous delivery of both necessary components, distinguishing it from monotherapies.

Active Ingredients and Composition

The active ingredients in Co-Eziday are Losartan Potassium and Hydrochlorothiazide, integrated alongside the tablet's solid excipients (base/vehicle). Losartan Potassium functions as an Angiotensin II Receptor Blocker (ARB), which works to oppose the effect of a major hormone that causes blood vessel tightening. Concurrently, Hydrochlorothiazide acts as a Thiazide Diuretic, promoting the increased elimination of excess sodium, chloride, and water through the kidneys. Pharmacological studies have supported this pairing, demonstrating that the dual composition effectively augments the overall pressure-lowering response compared to either agent used alone.

General Purpose and Therapeutic Benefit

The general purpose of the Losartan-Hydrochlorothiazide combination is the potent and stable blood pressure lowering required for long-term Cardiovascular Risk Management. A typical neutral use scenario for Co-Eziday is in managing chronic Hypertension, particularly when monotherapy with an ARB has proven insufficient to achieve target pressure goals. By facilitating robust and consistent antihypertensive effects, the medicine plays a direct role in systematic management of high pressure, thereby helping reduce the mechanical strain on the heart and arterial system.

Regulatory References

  1. Losartan Potassium and Hydrochlorothiazide Tablets (DailyMed/NIH)

What side effects are possible with Co-Eziday?

Possible Side Effects and Safety Information

The safety profile of Co-Eziday (Losartan/Hydrochlorothiazide) is defined by officially documented adverse reactions, classified by frequency and grouped into affected physiological systems. This information is derived from government regulatory sources, such as the FDA and EMA prescribing information.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions are classified as Common (occurring in 1 to 10 users in 100). These typically include dizziness, cough, and upper respiratory infection. Reactions classified as Uncommon (affecting 1 to 10 users in 1,000) involve systems such as the skin, gastrointestinal tract, and ears, and may include conditions like rash, abdominal pain, and tinnitus.

Serious Adverse Reactions and Systemic Constraints

Official labeling documents specific, clinically significant reactions and safety constraints. A serious adverse reaction associated with the use of the medicine is Angioedema (swelling of the face, lips, throat, and/or tongue). The medicine also carries a regulatory constraint due to the potential for Fetal/Neonatal Morbidity and Mortality, necessitating discontinuation if pregnancy is detected, particularly in the second and third trimesters.

Population and Contextual Safety Notes

The medicine is contraindicated in certain populations, including individuals with severe renal impairment (creatinine clearance < 30 mL/min) and severe hepatic impairment. Furthermore, the safety profile includes notes related to exposure timing: the risk of symptomatic hypotension may be greater at the start of treatment in susceptible patients, and long-term use of the hydrochlorothiazide component is associated with risks like Non-Melanoma Skin Cancer (NMSC), as observed in epidemiological studies. The use is also restricted in patients with Anuria or uncorrected refractory electrolyte imbalances.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Co-Eziday (Losartan/Hydrochlorothiazide) overdose is primarily defined by the combined effects of the drug components, resulting in two major clinical concerns: Profound Hypotension and Severe Fluid and Electrolyte Imbalance.

Documented clinical manifestations, as described in official labeling, include Dizziness, Fainting, Tachycardia (fast heart rate), or Bradycardia (slow heart rate). Severe outcomes can include Collapse, Seizure, or Acute Respiratory Distress Syndrome (ARDS), the latter being a rare, severe complication documented with the Hydrochlorothiazide component.

Overdose Management Focus Required Regulatory Statement
Urgent Action Required Immediate medical attention is required. Contact Emergency Services if the individual has collapsed, had a seizure, or cannot be awakened. Call Poison Control is the initial mandated step.
Treatment Approach Treatment is symptomatic and supportive; there is no specific antidote known. Management includes stabilizing blood pressure and continuous monitoring of renal function and serum potassium to correct fluid and salt depletion.

Regulatory documents note that neonates with in-utero exposure to the drug should be closely observed for hypotension and hyperkalemia. The overall severity classification is based on the potential for life-threatening hemodynamic instability and severe electrolyte disturbance.

Therapeutic Uses of Co-Eziday

What Co-Eziday Treats: Main Uses and Benefits

Co-Eziday (Losartan/Hydrochlorothiazide) is a combination treatment focused on the long-term management of high systemic blood pressure, generally used in conditions associated with systemic imbalance. It is applied in clinical settings when blood pressure is not adequately controlled on a single medication.

Therapeutic Focus and Key Benefits

This medicine is used for individuals diagnosed with Essential Hypertension who require sustained, daily assistance to maintain healthy pressure levels. The resulting therapeutic benefit contributes to achieving stable blood pressure lowering, which is relevant for managing this long-term condition and easing the overall symptom load on the cardiovascular system.

The primary therapeutic indications include conditions characterized by periods of heightened symptoms, such as Left Ventricular Hypertrophy (heart enlargement), and when additional management of discomfort is required because prior therapy has proven insufficient. The combination's components are applied in addressing the need for robust pressure control. This supportive benefit helps maintain a sense of stability when symptoms are more noticeable and plays a role in managing risks associated with major cardiovascular events.

Quick Fact: Relief for Systemic Strain
Supports the patient during difficult episodes by easing the overall symptom burden associated with chronic pressure elevation.

Eligibility and Restrictions for Use

Who Can and Cannot Use Co-Eziday?

Eligibility to use Co-Eziday (Losartan/Hydrochlorothiazide) is based on official regulatory labeling, primarily defining who is eligible and who is absolutely prohibited from using the medicine.

Official Eligibility Summary

Classification Status & Key Limitations
Approved Population Adults with essential hypertension whose blood pressure is not adequately controlled by single-agent therapy.
Pediatric Use Not established or not recommended in children and adolescents under 18 years of age.
Pregnancy/Lactation Contraindicated in the 2nd and 3rd trimesters of pregnancy; must be discontinued as soon as possible if pregnancy is detected. Not recommended while breastfeeding.

Absolute Contraindications

Co-Eziday must not be used by patients with the following conditions, as they represent an official prohibition of use:

  • Severe Organ Impairment: Including anuria, severe renal impairment (creatinine clearance <30 mL/min), and severe hepatic impairment.
  • Hypersensitivity: Known allergy to Losartan, Hydrochlorothiazide, or any sulfonamide-derived drug.
  • Dual RAS Blockade: Use with Aliskiren is contraindicated in patients with Diabetes Mellitus.

Use is also not recommended for titration in patients with mild-to-moderate hepatic impairment due to the fixed-dose formulation.

What should I know about interactions with other medicines?

Co-Eziday Interactions with other medicines and products

The interaction profile for Losartan/Hydrochlorothiazide is defined by regulatory mandates governing co-administration and documented effects on drug exposure.

Official Interaction Statements

Classification Interacting Substance/Class Documented Regulatory Requirement
Contraindicated Aliskiren Prohibited in patients with Diabetes Mellitus or renal impairment (GFR < 60 mL/min/1.73 m^2) due to dual blockade risk.
Exposure Modifier Fluconazole (Inhibitor) Documented to increase Losartan exposure (AUC) by up to 70%.
Exposure Modifier Rifampin (Inducer) Documented to reduce Losartan exposure (AUC) by up to 30%.
Pharmacodynamic Potassium Supplements Not recommended due to increased risk of hyperkalemia.
Pharmacodynamic Lithium Increased plasma levels of Lithium and subsequent toxicity risk are documented.
Pharmacodynamic NSAIDs Increased risk of renal impairment and reduced blood pressure lowering effect.
Absorption Timing Cholestyramine, Colestipol Must be taken 4 hours before or 4 to 6 hours after the resin to avoid reduced absorption of the diuretic component.

Population-Specific Notes

The combination is contraindicated in patients with severe hepatic impairment, as documented pharmacokinetic studies show significantly reduced Losartan clearance, leading to increased plasma concentrations. Furthermore, the co-administration of Aliskiren is explicitly prohibited in patients with pre-existing renal impairment.

Mechanism of Action

How Co-Eziday Works

Co-Eziday modulates the P38alpha/ MAPK signaling cascade, resulting in the inhibition of osteoclast activation. The compound functions as a selective antagonist on the IL-6 and TNFalpha receptors, mitigating pro-resorptive signals at the cellular surface. Intracellularly, Co-Eziday limits the downstream transcriptional activity of NFkappa B, which is a key regulator of cellular processes. This modulation alters the homeostatic balance between bone resorption and formation at the tissue level. The mechanism includes selective influence on ERK1/2 activity, subsequently reducing the gene expression of lytic enzymes, specifically Cathepsin K and Tartrate-Resistant Acid Phosphatase ( TRAP). Furthermore, the compound interacts with the JAK/ STAT signaling pathway, which is integral to the regulation of immunological and cellular differentiation processes within the bone microenvironment.

Dosage and Administration Information

How to Use Co-Eziday

Co-Eziday (Losartan Potassium and Hydrochlorothiazide) is used according to established guidelines. The combination is a prescription-only product intended for long-term, sustained management.

Official Administration Guidelines

Instruction Detail
Route of Administration The product is administered orally as a tablet.
Dosing Schedule The usual starting dose for adults is 50 mg/12.5 mg once daily. The maximum recommended dosage is 100 mg/25 mg once daily.
Timing in relation to meals The tablet may be administered with or without food.
Preparation requirements No preparation or reconstitution is needed; the tablet must be swallowed whole with a sufficient amount of liquid.

Usage Structure and Titration

Co-Eziday is structured as a once-daily regimen to maintain consistent blood pressure control. Dose adjustment, known as titration, should be considered only after approximately three to four weeks of therapy if the initial dosage fails to achieve adequate control.

If a dose is missed, it is typically skipped entirely, and the regular administration schedule is resumed; doses are not doubled to compensate.

Administration parameters for specific populations are also defined. For instance, the combination is generally not recommended for use in children and adolescents, or in patients with severe renal or hepatic impairment. These constraints define the boundaries for appropriate use.

Recent Clinical Evidence

Research evidence / Overview of studies for Co-Eziday

Evidence for Use in Essential Hypertension

Research exploring Co-Eziday (Losartan/Hydrochlorothiazide) was conducted using Randomized Controlled Trials (RCTs) and systematic reviews. These studies were evaluated in research exploring the fixed-dose combination compared to placebo and its ingredients studied alone. Researchers monitored changes in systolic and diastolic blood pressure (BP) readings and the achievement of specific BP goals in adult populations. Findings described patterns of measured BP levels in the combination group. Research explored differences in measured BP levels in the combination group compared to when Losartan or Hydrochlorothiazide were studied alone. Comparative evidence for long-term event reduction in this population is generally lacking.

Evidence for Use in Hypertension with Left Ventricular Hypertrophy (LVH)

A key part of the research was conducted in a large, long-term cardiovascular outcomes trial involving older adults with LVH. This study was designed to track serious events, including stroke, myocardial infarction, and cardiovascular death. Studies monitored the frequency of these outcomes compared to an active comparator treatment regimen. The design, however, involved the non-randomized addition of the diuretic agent, meaning the isolated contribution of each component is not fully established.

Research Gaps and Uncertainty

Findings from the large outcome study indicated that the observed patterns related to stroke incidence did not apply to the subgroup of self-identified Black patients included in the research. Subgroup findings are uncertain, and results apply only to the specific populations studied. While some studies have explored use in pediatric populations (6 years and older), data for certain groups remain insufficient for drawing universal conclusions. Furthermore, comparative evidence against some other antihypertensive combinations is lacking, and long-term effects on non-blood pressure-related health outcomes are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Co-Eziday (FAQ)

Q: What is Co-Eziday used for?

Co-Eziday is prescribed to help manage certain conditions, typically relating to X or Y. The specific uses are outlined in the official prescribing information approved by the regulatory bodies.

Q: How should I take Co-Eziday?

The way you should take this medication, including the dose and frequency, is determined by your prescribing healthcare provider based on your specific health needs. Always follow the instructions provided by your doctor and those on the product label.

Q: What if I miss a dose of Co-Eziday?

If you miss a dose, guidance for what to do can usually be found on the patient information leaflet that comes with the medication. It is generally recommended to consult your doctor or pharmacist for specific advice tailored to your treatment schedule.

Q: Can I stop taking Co-Eziday once I feel better?

Changing your treatment plan, including stopping or reducing the dose, should only be done after discussing it with your healthcare provider. Abruptly stopping some medications can sometimes lead to different effects.

Q: What are the common side effects of Co-Eziday?

Like all medicines, Co-Eziday may be associated with side effects. The product label lists common reported effects, which may include things such as A, B, and C. If you experience any severe or concerning symptoms, contact your doctor immediately.

How should Co-Eziday be stored and disposed of?

How to Store and Dispose of Co-Eziday?

The official regulatory labeling specifies strict conditions for storing and disposing of Co-Eziday (Losartan/Hydrochlorothiazide) to maintain its stability and effectiveness.

Required Storage Conditions

Co-Eziday must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from excessive heat, light, and moisture and kept in its original container, which must remain tightly closed.

Child Safety and Disposal

It is an explicit requirement to keep Co-Eziday out of the sight and reach of children.

Expired or unused medicine must be disposed of according to local regulatory requirements. The product should not be disposed of in household wastewater or trash, as required by pharmaceutical waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Co-Eziday found in:

A-Z Index: